A stem-cell derived dopaminergic progenitor product, STEM-PD, showed feasibility and a favorable early safety profile in a Phase 1/2 open-label trial in Parkinson’s disease. The study involved eight participants receiving transplants of STEM-PD, a cryopreserved off-the-shelf product derived from human pluripotent stem cells. Published in Nature Medicine, the trial reported no serious side effects linked to the transplanted cells during the first year of follow-up. The findings support continued development toward larger cohorts, with investigators framing the approach as a pathway to replace lost dopamine neurons. The trial adds to regenerative momentum in neurodegeneration by delivering human proof-of-concept on delivery and short-term tolerability.